Summary
Highlights
The standard approach to depression treatment has been based on the monoamine deficiency hypothesis, which suggests a deficiency or underactivity of one of three neurotransmitters in the brain. However, with over a hundred neurotransmitters and billions of neuronal connections, this hypothesis is considered limited.
Initially, the primary cause of depression was thought to be abnormalities in serotonin or norepinephrine. However, these did not fully explain depression symptoms. Instead, chemical messengers like glutamate and GABA, which are abundant and regulate brain changes over time, are now being considered as alternative causes for depression symptoms.
Severe and chronic stress, often experienced by individuals with depression, can lead to the loss of connections between nerve cells. This results in inefficient and noisy communication within brain circuits involved in regulating mood and emotion, with the loss of these synaptic connections contributing to the biology of depression.
Understanding the neurobiology of depression is crucial for two reasons: it helps in comprehending disease development and progression, allowing for targeted treatments. A depressed brain differs from a healthy one, and effective treatment can return the brain to a healthy state.
Treating depression is often a long-term process, and for many, it's a long-term disorder, highlighting the need for new and innovative treatments, especially for those who haven't responded to previous therapies.
Psychiatry is entering a new era, shifting from the monoaminergic deficiency model to a more comprehensive understanding of the brain as a complex neurochemical organ, which represents a significant paradigm shift.